1-3 of 3
Catherine Brand
Close
Sort by
Journal Articles

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) Results in a High Response Rate in Patients with Refractory Multiple Myeloma (RMM).

Rachid Baz, MD, Toni K. Choueiri, MD, Rony Abou Jawde, MD, Bridget McGowan, Yvette Ellis, Catherine Brand, Mohamad A. Hussein, MD
Journal: Blood
Blood (2005) 106 (11): 2559.
https://doi.org/10.1182/blood.V106.11.2559.2559
Published: 2005
Journal Articles

Aspirin Decreases the Thrombotic Complications (DVT) of Liposomal Doxorubicin, Vincristine, Decreased Frequency Dexamethasone and Thalidomide (DVd-T) Treatment of Multiple Myeloma (MM).

Rachid Baz, M.D., Kandice Marchant, M.D., Erin O. Yiannaki, M.S., Luba Platt, Catherine Brand, Elisa Tso, M.D., Mohamad A. Hussein, M.D.
Journal: Blood
Blood (2004) 104 (11): 2397.
https://doi.org/10.1182/blood.V104.11.2397.2397
Published: 2004
Journal Articles

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients.

Mohamad A. Hussein, MD, Mary Ann Karam, RN, Catherine Brand, Greg L. Pearce, Janice Reed, RN, Kellie Bruening, Paul Sartori, Gordan Srkalovic, MD, PhD, Marta Olesnyckyj, RN, Robert Knight, MD, Kathe Balinski, RN, MA, Jerome Zeldis, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 208.
https://doi.org/10.1182/blood.V104.11.208.208
Published: 2004